巨细胞动脉炎糖皮质激素治疗模式与累积负担:法国全国队列研究
累积激素暴露与死亡率、严重感染、主要不良心血管事件及骨质疏松性骨折相关,即使低剂量亦存在风险。
要点
- 高剂量激素轨迹随时间下降,但2022年诊断者2年平均累积剂量仍达7.6 g。
- 托珠单抗处方至2022年超过25%,甲氨蝶呤使用至2020年增加后趋于平稳。
- 每克激素与死亡率升高相关(HR 1.024,95%CI 1.021–1.027)。
核心结论
- 尽管高剂量激素使用减少,巨细胞动脉炎患者累积激素暴露仍 substantial,且与不良结局相关,即使最低剂量亦存在风险。
研究设计与样本
- 采用潜类别增长模型识别激素使用轨迹,多变量生存模型评估累积暴露与结局的关联。
主要发现
- 识别出四种激素使用轨迹,其中两种高剂量轨迹随时间下降。
- 2022年诊断患者2年平均累积激素剂量仍达7.6 g。
- 甲氨蝶呤使用至2020年增加后趋于平稳,托珠单抗处方上升至2022年超过25%。
- 男性及基线使用甲氨蝶呤或托珠单抗与更快减量相关,年龄>75岁、高血压、肾脏及神经退行性疾病与更慢减量相关。
- 每克激素与更高死亡率相关(HR 1.024,95%CI 1.021至1.027)。
临床怎么用
- 临床应关注巨细胞动脉炎患者累积激素剂量,即使低剂量暴露亦需监测感染、心血管事件及骨折风险。
- 对高龄、高血压、肾脏及神经退行性疾病患者减量可能更慢,需个体化评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Recent advances in giant cell arteritis (GCA) management aim to reduce glucocorticoid (GC). We described changes in treatment patterns over time in real life and assessed associations between cumulative GC use and adverse outcomes. METHODS: This retrospective population-based study used the French national health insurance database (Système National des Données de Santé) and included 18 301 incident GCA cases between 2010 and 2022. Latent class growth modelling identified GC use trajectories. We described trends in cumulative dose and sparing agent use. Multivariable survival models assessed factors associated with sustained GC-free remission and association between GC cumulative exposure and mortality, serious infections, major adverse cardiovascular events (MACE) and osteoporotic fractures. RESULTS: Four GC use trajectories were identified. Two high-dose trajectories declined over time. Yet, mean 2-year cumulative GC dose remained high, reaching 7.6 g among patients diagnosed in 2022. Methotrexate use increased until 2020 and plateaued thereafter while tocilizumab prescriptions rose, reaching over 25% in 2022. Male sex and baseline methotrexate or tocilizumab use were associated with faster GC tapering, while age >75 years, hypertension, kidney and neurodegenerative diseases were associated with slower tapering. Each gram of GC was associated with higher mortality (HR per gram 1.024, 95% CI 1.021 to 1.027). Yearly cumulative exposure to doses ≤5 mg/day was associated with increased infection (HR 1.13, 95% CI 1.00 to 1.29) and MACE (HR 1.04, 95% CI 1.01 to 1.08). CONCLUSION: Despite reductions in high-dose use, cumulative GC exposure in GCA remains substantial and associated with adverse outcomes, even at the lowest doses.
引用
- Beydon M, Lacaille D, Fautrel B, et al. Glucocorticoid in giant cell arteritis: real-world treatment patterns over time and associated burden in a nationwide hospital-based study within the French health insurance database. RMD Open. 2026. PMID: 42414038. doi:10.1136/rmdopen-2026-006866
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。